Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep695 | Pituitary and Neuroendocrinology | ECE2022

Epidemiological description of 20 years of experience in the management of insulinomas in a third level hospital

Maricel Rivas Montenegro Alejandra , Ramos Roberto Jose An ez , Belinchon Sergio Santos , Gonzalez Fernandez Laura , Moreno Diego Mun oz , Fernandez Fernandez Elisa , Salas Marcel Sambo , Hualpa Juan Carlos Percovich , Gonzalez Albarran Olga , Garcia Centeno Rogelio

Introduction: Insulinoma, despite its low incidence of 0.4%, it is the most common functioning pancreatic neuroendocrine tumor. Most are benign, solitary and sporadic. Around 10% can be malignant and 5-10% are part of MEN-1. On certain occasions, the differential diagnosis is difficult when there is a history of Diabetes Mellitus (DM). Our objective was to describe clinical-epidemiological data and its diagnostic-therapeutic management.Materials and Meth...

ea0070aep654 | Pituitary and Neuroendocrinology | ECE2020

Our experience with lu-dotatate in patients with neuroendocrine tumors in a tertiary hospital

Munoz Diego , Carlos Percovich Hualpa Juan , Weber Bettina , Atencia Goñi José , González Fernández Laura , Miguélez González María , Brox Torrecilla Noemí , José Añez Ramos Roberto , Maricel Rivas Montenegro Alejandra , López Guerra Aurelio , Lucía Olmedilla Isishi Yoko , Ángeles Vélez Romero María , Ágreda García Javier , Picallo Pérez María , Monereo Megías Susana , García Centeno Rogelio

Introduction: Lutetium-177-DOTATATE (Lu177) is approved in patients with well-differentiated (G1 and G2) neuroendocrine tumors (NETs) positive to somatostatin receptors, progressive and unresectable or metastatic. Lu177 has been shown to increase progression-free survival and the quality of life of these patients.Material and Methods: Retrospective descriptive study of a series of 15 cases with NETs treated with Lu177. Demographic data, tumor characteris...